Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Genentech
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Étude GP28153 : étude de phase 1, en escalade de dose, randomisée, évaluant la sécurité d’emploi, la tolérance et la pharmacocinétique du GDC-0575 administré en monothérapie ou en association avec la gemcitabine, chez des patients ayant une tumeur solide réfractaire ou un lymphome. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cette étude est d’évaluer la sécurité d’emploi, la tolérance et la pharmacocinétique du GDC-0575 administré seul ou en association avec la gemcitabine, chez des patients ayant une tumeur...
Country
France
organs
Tumeurs solides
,
Lymphomes hodgkinien (maladie de Hodgkin)
,
Lymphomes non hodgkinien
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study Of Xolair (Omaluzimab) In Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Anithistamine Treatment (H1)
To evaluate the efficacy of single doses of omalizumab compared with placebo in patients with refractory chronic idiopathic urticaria (CIU) receiving concomitant H1 antihistamine therapy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
Imaging study in patients with Crohn`s Disease Estudio con técnicas de imagen en pacientes con enfermedad de Crohn
To estimate the test-retest reliability (precision) of MRE assessments of CD activity in the small bowel in a global setting Calcular la fiabilidad prueba-reprueba (precisión) de las evaluacione...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
Etude GO30103 : étude de phase 1a-1b visant à évaluer l’innocuité et la pharmacocinétique du MTIG7192A seul ou en association avec l’atézolizumab chez des patients ayant une tumeur localement avancée ou métastatique. [essai clos aux inclusions]
Une tumeur correspond au développement d’un tissu nouvellement formé au sein d’un tissu normal. Elle peut être bénigne (non cancéreuse) ou maligne (cancer). Les cellules cancéreuses sont initialement ...
Country
France
organs
Tout Cancer
Specialty
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+RO5072759 (GA101) in Patients With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma Studie bezpečnosti a účinnosti Bendamustinu oproti Bendamustinu v kombinaci s GA101 u pacientů s non-Hodgkinským lymfomem refrakterním na Rituximab
To evaluate clinical benefit in terms of PFS, as assessed by an IRF, for GA101 when used in combination with bendamustine compared with bendamustine alone in patients with indolent NHL refractory to p...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model
To evaluate the reduction in AUC of virus load from the nasopharyngeal mucosa in the MHAA4549A treatment group compared to placebo
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
A PHASE II, SINGLE-ARM, OPEN-LABEL STUDY OF THE SAFETY,PHARMACOKINETICS, AND EFFICACY OF MULTIPLE DOSES OF APOMAB ADMINISTERED INTRAVENOUSLY IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH FOLLICULAR, CD20-POSITIVE B-CELL NON-HODGKIN’S LYMPHOMA THAT HAS PROGRESSED FOLLOWING PREVIOUS RITUXIMAB THERAPY
To evaluate the safety and tolerability of Apomab when combined with rituximab for the treatment of patients with relapsed follicular, CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). To make a prel...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Genentech Inc
Update Il y a 4 ans
Clinical study to evaluate MPDL3280A-RO5541267 in patients with PD-L1- positive locally or metastatic non-small cell lung cancer
The primary efficacy objective for this study is to evaluate the efficacy of MPDL3280A in patients with PD-L1−positive locally advanced or metastatic NSCLC, as measured by investigator-assessed ORR ac...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Genentech
Update Il y a 4 ans
GADOLIN : Essai de phase 3 randomisé comparant l’efficacité et la tolérance de l’association de la bendamustine et du RO5072759 (GA101) à la bendamustine seule, chez des patients ayant un lymphome hodgkinien indolent réfractaire au rituximab. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de comparer l’efficacité de l’association de la bendamustine et du GA101 à la bendamustine seule, chez des patients ayant un lymphome hodgkinien indolent réfractaire au rit...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Genentech Inc
Update Il y a 4 ans
A randomized study of the safety and efficacy of a novel drug, DNIB0600A, compared to chemotherapy when given intravenously to patients with ovarian cancer
To evaluate the efficacy of DNIB0600A compared with pegylated liposomal doxorubicin (PLD) in patients with PROC as assessed by PFS in patients with NaPi2b-high tumors as well as in the overall patient...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
Next